Finance

Lists
Q3 2026 earnings • 6:30 PM today
See details
EL:EPA
EssilorLuxottica SA
€152.05
-1.52%
(-2.35) 1D
Oct 19, 5:35:22 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for EL...
Open
€151.60
High
€153.20
Low
€149.20
Mkt. cap
70.70B
Avg. vol.
793.73K
Volume
805.88K
P/E ratio
28.38
52-wk high
€323.80
52-wk low
€138.30
EPS
€5.36
Shares outstanding
464.25M
No. of employees
214K
Open
€151.60
High
€153.20
Low
€149.20
Mkt. cap
70.70B
Avg. vol.
793.73K
Volume
805.88K
P/E ratio
28.38
52-wk high
€323.80
52-wk low
€138.30
EPS
€5.36
Shares outstanding
464.25M
No. of employees
214K
News stories
From web sources and news partners
Profile
EssilorLuxottica SA is a Franco-Italian vertically integrated multinational holding company registered in Charenton-Le-Pont and headquartered both in Paris and Milan. It designs, produces and markets ophthalmic lenses, equipment and instruments, prescription glasses and sunglasses. It was founded on 1 October 2018, and its name is an amalgamation of the two major corporations which merged to create it; the French Essilor and the Italian Luxottica. The two companies have, since the merger, been restructured as subsidiaries of the new entity. Under the terms of the merger agreement, Essilor would purchase Luxottica, but Luxottica's leadership would be guaranteed prominent positions in the newly-formed corporation as well as some seats on its board of directors; the Luxottica founder, Leonardo Del Vecchio, was notably designated chairman. The first few years of EssilorLuxottica post-merger were marred by disputes over leadership roles, but Del Vecchio was able to bring them to a satisfactory end. Essilor and Luxottica were respectively the world's leading manufacturers of ophthalmic lenses and of eyeglasses; upon the merger, EssilorLuxottica thus became a monopoly. Wikipedia
About EssilorLuxottica SA
CEOFrancesco Milleri
Employees214K
FoundedOct 1, 2018
Headquarters-
SectorMedical device
Websiteessilor.com
Next call in 10:21:50
Today, 6:30 PM
Fiscal period
Q3 2026
- / -
Revenue / Est. (EUR)
- / 7.35B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
7.23B
7.23B
7.41B
7.41B
Cost of goods sold
3.08B
3.08B
2.77B
2.77B
Cost of revenue
3.08B
3.08B
2.77B
2.77B
Research and development expenses
169.00M
169.00M
166.50M
166.50M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.26B
3.26B
3.33B
3.33B
Operating expense
3.42B
3.42B
3.50B
3.50B
Total operating expenses
6.50B
6.50B
6.27B
6.27B
Operating income
737.50M
737.50M
1.14B
1.14B
Other non operating income
-9.50M
-9.50M
5.00M
5.00M
EBT including unusual items
639.50M
639.50M
1.09B
1.09B
EBT excluding unusual items
688.00M
688.00M
1.08B
1.08B
Income tax expense
144.50M
144.50M
271.00M
271.00M
Effective tax rate
22.60%
22.60%
24.81%
24.81%
Other operating expenses
-9.00M
-9.00M
-1.00M
-1.00M
Net income
464.00M
464.00M
783.00M
783.00M
Net profit margin
6.41%
6.41%
10.57%
10.57%
Earnings per share
-
-
-
-
Interest and investment income
25.00M
25.00M
19.50M
19.50M
Interest expense
-83.50M
-83.50M
-94.00M
-94.00M
Net interest expenses
-58.50M
-58.50M
-74.50M
-74.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.26B
1.26B
1.67B
1.67B
Gain or loss from assets sale
1.50M
1.50M
-21.00M
-21.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps